Pulmonary Function in Patients With Hodgkin's Disease Receiving Bleomycin-Based Chemotherapy

Completed

Conditions studied: Hodgkin's Disease

In brief

The purpose of this study is to find out the impact Bleomycin-containing chemotherapy, given with or without chest radiation therapy, on patients' lung function over time.

Key facts

Study ID

NCT00165438

Run by

Dana-Farber Cancer Institute

People needed

60

Starts

2001-10-01

Expected to finish

2010-01-01

Last updated by the study team

2012-12-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with newly diagnosed classical Hodgkin's disease, with mediastinal involvement
• Bleomycin-based chemotherapy alone or in combination with mediastinal irradiation

You may not qualify if…

• Prior chest irradiation
• Mediastinal irradiation received at an outside institution
• Refractory or progressive disease on treatment

Where it is running

• Brigham and Women's Hospital — Boston, Massachusetts, United States
• Dana-Farber Cancer Institute — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.